Mycophenolate mofetil inhibits tumor growth and angiogenesis in vitro but has variable antitumor effects in vivo, possibly related to bioavailability

Transplantation

Volumn 83, Issue 5, 2007, Pages 607-614

  Koehl, Gudrun E ^a   Wagner, Ferdinand ^a   Stoeltzing, Oliver ^a   Lang, Sven A ^a   Steinbauer, Markus ^a   Schlitt, Hans J ^a   Geissler, Edward K ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Angiogenesis; Cancer; Immunosuppressive dose; Mycophenolate mofetil; Posttransplant malignancy

Indexed keywords

MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL TRANSPLANTATION; COLON ADENOCARCINOMA; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; STOMACH ADENOCARCINOMA; TUMOR CELL; TUMOR CELL CULTURE; TUMOR VASCULARIZATION; TUMOR VOLUME; VASCULAR RING;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; AORTA; BIOLOGICAL AVAILABILITY; CELL LINE, TUMOR; COLONIC NEOPLASMS; ENDOTHELIUM, VASCULAR; HUMANS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MUSCLE, SMOOTH, VASCULAR; MYCOPHENOLIC ACID; NEOVASCULARIZATION, PATHOLOGIC; STOMACH NEOPLASMS; UMBILICAL VEINS;

EID: 33947324675     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000253756.69243.65     Document Type: Article

References (23)

1. Penn I. Cancers complicating organ transplantation. N Engl J Med 1990; 323: 1767.
2. Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation 2005; 80: S254.
3. McDonald S, Excell L, Livingston B. Deaths. ANZDATA Registry, 2005. www.anzdata.org.au
4. Carter SB, Franklin TJ, Jones DF, et al. Mycophenolic acid: an anticancer compound with unusual properties. Nature 1969; 223: 848.
5. Suzuki S, Kimura T, Ando K, et al. Antitumor activity of mycophenolic acid. J Antibiot 1969; 22: 297.
6. Tressler RJ, Garvin LJ, Slate DL. Antitumor activity of mycophenolate mofetil against human and mouse tumors in vivo. Int J Cancer 1994; 57: 568.
7. Takebe N, Cheng X, Fandy TE, et al. IMP dehydrogenase inhibitor mycophenolate mofetil induces caspase-dependent apoptosis and cell cycle inhibition in multiple myeloma cells. Mol Cancer Ther 2006; 5: 457.
8. Engl T, Makarevic J, Relja B, et al. Mycophenolate mofetil modulates adhesion receptors of the beta1 integrin family on tumor cells: impact on tumor recurrence and malignancy. BMC Cancer 2005; 5: 4.
9. Silva SL, Silva SF, Cavalcante RO, et al. Mycophenolate mofetil attenuates Walker's tumor growth when used alone, but the effect is lost when associated with cyclosporine. Transplant Proc 2004; 36: 1004.
10. Brattain MG, Strobel-Stevens J, Fine D, et al. Establishment of mouse colonic carcinoma cell lines with different metastatic properties. Cancer Res 1980; 40: 2142.
11. Lee WA, Gu L, Miksztal AR, et al. Bioavailability improvement of mycophenolic acid through amino ester derivatization. Pharm Res 1990; 7: 161.
12. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47: 85.
13. Nicosia RF, McCormick JF, Bielunas J. The formation of endothelial webs and channels in plasma clot culture. Scan Electron Microsc 1984; Pt 2: 793-799.
14. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128.
15. Koehl G, Gaumann A, Zuelke C, et al. Development of de novo cancer in p53 knock-out mice is dependent on the type of long-term immunosuppression used. Transplantation 2006; 82: 741.
16. Sweeney MJ, Gerzon K, Harris PN, et al. Experimental antitumor activity and preclinical toxicology of mycophenolic acid. Cancer Res 1972; 32: 1795.
17. Huang Y, Liu Z, Huang H, Liu H, Li L. Effects of mycophenolic acid on endothelial cells. Int Immunopharmacol 2005; 5: 1029.
18. Voisard R, Viola S, Kaspar V, et al. Effects of mycophenolate mofetil on key pattern of coronary restenosis: a cascade of in vitro and ex vivo models. BMC Cardiovasc Disord 2005; 5: 9.
19. Koehl G, Andrassy J, Guba M, et al. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation 2004; 77: 1319.
20. Stracke S, Ramudo L, Keller F, et al. Antiproliferative and overadditive effects of everolimus and mycophenolate mofetil in pancreas and lung cancer cells in vitro. Transplant Proc 2006; 38: 766.
21. Geissler EK, Schlitt HJ. The relation between immunosuppressive agents and malignancy. Curr Opin Organ Transpl 2004; 9: 394.
22. Nakamura M, Iwahashi M, Nakamori M, et al. Dendritic cells genetically engineered to simultaneously express endogenous tumor antigen and granulocyte macrophage colony-stimulating factor elicit potent therapeutic antitumor immunity. Clin Cancer Res 2002; 8: 2742.
23. + T cells with IFN-γ-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol 2003; 171: 5931.